智通财经APP获悉，石药集团(01093)再涨超4%，截至发稿，涨3.81%，报6.54港元，成交额8.59亿港元。
消息面上，石药集团日前公布，集团开发的一款首创表皮生长因子受体（EGFR）抗体偶联药物(ADC)CPO301获美国食品药品监督管理局（FDA）授予第三项快速通道资格，用于治疗不伴有EGFR 突变或其他驱动基因改变(AGA)，且既往经含铂化疗和抗PD - (L) 1抗体治疗后出现疾病进展的晚期或转移性非鳞状非小细胞肺癌成年患者。
此外，由石药集团开发的双特异性融合蛋白药物JMT106已获中华人民共和国国家药品监督管理局批准，可以在中国开展临床试验。该产品亦已于2024年1月获得美国食品药品监督管理局(FDA)批准在美国开展临床试验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.